4 results
To test the hypothesis that LY3314814, administered orally at doses of 20 and 50 mg daily for 78 weeks, will slow the decline of AD ascompared with placebo in patients with mild AD dementia.
Primary objective: Determine for different control algorithms and robotic modules whether the algorithm and/or robotic module is effective in providing the patient with the required support and measure bringing about the desired changes in the…
Objectives:Primary Objectives:1. To evaluate the efficacy of BAN2401 compared to placebo by establishing the ED90 (as defined in theprotocol) for BAN2401 on the derived Composite Clinical Score at 12 months of treatment in subjects withEarly…
The primary aim of this study is to assess the effect of weight loss in obese subjects, brought about by non-surgical methods, on all types of gastroesophageal reflux (gaseous, liquid and mixed, acid and nonacid), as measured by ambulatory pH/…